ClinicalTrials.gg
Active, not recruitingNCT03496883FASTESTUpdated Jan 21, 2026

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

A Phase 3 interventional study of Recombinant Activated Factor VII (rFVIIa) and Placebo in Intracerebral Hemorrhage, sponsored by Joseph Broderick, MD. Active, not recruiting at 88 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Joseph Broderick, MD · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
860
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing recombinant FVIIa in Cerebral Hemorrhage — 1 open to participants now, 2 under way, 2 of them phase 3. recombinant FVIIa · Cerebral Hemorrhage.

Planned enrollment
Largest of 11
860 · median 90
Started
2021
the only one that year
Phase 3
3 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
2 of 11
Joseph Broderick, MD

Among the 11 studies testing recombinant FVIIa in Cerebral Hemorrhage, this one has the largest planned enrollment, is the only one that started in 2021, is one of 3 in phase 3, and was the 10th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 172 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

1 of the 11 studies testing recombinant FVIIa in Cerebral Hemorrhage is open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About recombinant FVIIa

recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Cerebral Hemorrhage studies recruiting now, 59 (52%) set no upper age limit and 9 (8%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing recombinant FVIIa in Cerebral Hemorrhage, or all of them as a file.
02

Study summary

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.

Read the detailed description

The investigators will perform a global, Phase III, randomized, double-blind controlled trial of rFVIIa plus best standard therapy vs. placebo and best standard therapy alone. The investigators will include participants with a volume of ICH ≥ 2 and \< 60 cc, no more than a small volume of intraventricular hemorrhage (IVH) (IVH score ≤ 7), age ≥ 18 and ≤ 80, Glasgow Coma Scale of ≥ 8, and treated within 120 minutes from stroke onset. To minimize time-to-treatment, the study will use emergency research informed consent procedures (including exception from informed consent (EFIC) in the United States) and mobile stroke units (MSUs), with a goal of ½ of participants treated within 90 minutes, as accomplished in the NINDS t-PA trials. The FASTEST Trial will include approximately 100 hospital sites and at least 15 MSUs in the NINDS-funded StrokeNet and key global institutions with large volumes of ICH patients and the ability to treat them within 120 minutes of stroke onset. Recruitment of 860 participants over 3½ years is planned. Countries participating in the trial include the United States, Canada, Japan, Germany, Spain, and the United Kingdom. Involving other countries may be possible in the future depending upon recruitment needs.

Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg. The primary outcome (ordinal mRS with the following categories: 0-2, 3, and 4-6) will be determined at 180 days, but participants will be followed by remote assessment at 30 days and 90 days. To measure growth of ICH, all participants will have a standard of care baseline non-contrast CT of the head and a repeat scan at 24 hours. Centralized volumetric measurements of ICH, IVH, and edema will be performed for both time points.

Novo Nordisk A/S will manufacture and supply rFVIIa as a research medication for use in the FASTEST Trial. Novo Nordisk A/S will also manufacture and supply matching placebo that is identical to rFVIIa in appearance and administration.

03

Conditions studied

  • Intracerebral Hemorrhage

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18-80 years, inclusive
  2. Patients with spontaneous ICH
  3. Able to treat with study medication (rFVIIa/placebo) within 120 minutes of stroke onset or last known well
  4. Efforts to obtain per EFIC guidelines (U.S.) or adherence to country-specific emergency research informed consent regulations (Canada, Germany, Spain, U.K., Japan)

Exclusion criteria

Exclusion Criteria:

  1. Score of 3 to 7 on the Glasgow Coma Scale
  2. Secondary ICH related to known causes (e.g., trauma, aneurysm, arteriovenous malformation (AVM), oral anticoagulant use (vitamin K antagonists or novel oral anticoagulants) within the past 7 days, coagulopathy, etc.)
  3. ICH volume \< 2 cc or ≥ 60 cc
  4. Blood filling 2/3 or more of one lateral ventricle of the brain, OR, blood filling at least 1/3 of both lateral ventricles.
  5. Pre-existing disability (mRS > 2)
  6. Symptomatic thrombotic or vaso-occlusive disease in past 90 days (e.g., cerebral infarction, myocardial infarction, pulmonary embolus, deep vein thrombosis, or unstable angina)
  7. Clinical or evidence of ST elevation consistent with acute myocardial ischemia
  8. Brainstem location of hemorrhage (patients with cerebellar hemorrhage may be enrolled)
  9. Refusal to participate in study by patient, legal representative, or family member
  10. Known or suspected thrombocytopenia (unless current count documented above 50,000/μL)
  11. Unfractionated heparin use with abnormal
  12. Pro-coagulant drugs within 24 hours prior to patient enrollment into the FASTEST trial (example, tranexamic acid or aminocaproic acid)
  13. Low-molecular weight heparin use within the previous 24 hours
  14. Recent (within 90 days) carotid endarterectomy or coronary or cerebrovascular angioplasty or stenting
  15. Advanced or terminal illness or any other condition the investigator feels would pose a significant hazard to the patient if rFVIIa were administered
  16. Recent (within 30 days) participation in any drug or device trial or earlier participation in any investigational drug or device trial for which the duration of effect is expected to persist until to the time of FASTEST enrollment
  17. Planned withdrawal of care or comfort care measures
  18. Patient known or suspected of not being able to comply with trial protocol (e.g., due to alcoholism, drug dependency, or psychological disorder)
  19. Known or suspected allergy to trial medication(s), , or related products
  20. to study medication
  21. Previous participation in this trial (previously randomized)
  22. Females of who are known to be pregnant or within 12 weeks post-partum and/or lactating at time of enrollment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
860 participants (estimated)

Study arms

  • Active comparator
    Recombinant Activated Factor VII (rFVIIa)

    rFVIIa given as IV injection over 2 minutes within 120 minutes of stroke onset

    Biological: Recombinant Activated Factor VII (rFVIIa)

  • Placebo comparator
    Placebo

    Matching placebo given as IV injection over 2 minutes within 120 minutes of stroke onset

    Biological: Placebo

Interventions

  • Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.

    Also known as: NovoSeven, NiaStase

  • BiologicalPlacebo

    Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.

06

What researchers measure

Primary outcomes

  1. Modified Rankin Scale (mRS)

    Ordinal distribution with the following steps: 0-2, 3, 4-6

    Time frame: 180 days

Secondary outcomes

  1. mRS

    Utility-weighted

    Time frame: 180 days

  2. mRS

    Score of 0-2

    Time frame: 180 days

  3. EQ-5D

    Quality of life scale

    Time frame: 180 days

  4. Change in the volume of ICH and ICH+IVH

    As measured by non-contrast CT of the head

    Time frame: Between baseline CT and 24-hour CT

  5. mRS

    Ordinal distribution

    Time frame: 90 days

  6. EQ-5D

    Quality of life scale

    Time frame: 90 days

  7. mRS

    Ordinal distribution

    Time frame: 180 days

07

Study locations

88 sites
08

References and documents

Publications

  • Broderick JP, Naidech AM, Elm JJ, Toyoda K, Dowlatshahi D, Demchuk AM, Khatri P, Steiner T, Bath PM, Audebert HJ, Vagal A, Yoshimura S, Mayer SA, Wang LL, Sabagha N, Mocco JD, Molina C, Aviv R, Stinson E, Quadri SA, Carrozzella J, Huynh T, Phan A, Beall J, Davis I, Sakai N, Ohta T, Yokosawa M, Hara T, Sangha N, Morita K, Dominc Tse MY, Streib CD, Miyashita F, Silva Y, Nagakane Y, Gheorghiu T, Sun CH, Hirano T, Poli S, Izumo T, Fukuda-Doi M, Ihara M, Koga M, Buck B, Walsh KB, Spokovny I, Grotta JC; FASTEST Investigators. Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026 Feb 21;407(10530):773-783. doi: 10.1016/S0140-6736(26)00097-8. Epub 2026 Feb 4. PubMed 41653933 ↗
  • Yu W, Alexander MJ. Spontaneous intracerebral hemorrhage: Recent advances and critical thinking on future clinical trial design. Chin Med J (Engl). 2024 Dec 20;137(24):2899-2906. doi: 10.1097/CM9.0000000000003408. Epub 2024 Dec 10. No abstract available. PubMed 39654449 ↗
  • Eilertsen H, Menon CS, Law ZK, Chen C, Bath PM, Steiner T, Desborough MJ, Sandset EC, Sprigg N, Al-Shahi Salman R. Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage. Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD005951. doi: 10.1002/14651858.CD005951.pub5. PubMed 37870112 ↗
  • Naidech AM, Grotta J, Elm J, Janis S, Dowlatshahi D, Toyoda K, Steiner T, Mayer SA, Khanolkar P, Denlinger J, Audebert HJ, Molina C, Khatri P, Sprigg N, Vagal A, Broderick JP. Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial. Int J Stroke. 2022 Aug;17(7):806-809. doi: 10.1177/17474930211042700. Epub 2021 Sep 5. PubMed 34427473 ↗

Related links

Individual participant data

Plan to share: Yes — Results to be reported on ClinicalTrials.gov, and trial database prepared for NINDS for sharing with other investigators

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Available 12 months after publication of primary results

Access criteria: Approval by NINDS

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Jan 2028, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2018
First posted
Apr 12, 2018
StartActual
Dec 3, 2021
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2028
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03496883
Lead sponsor
Joseph Broderick, MD
Responsible party
Joseph Broderick, MD (Principal Investigator, University of Cincinnati) — Sponsor-investigator
First posted
Apr 12, 2018
Start date
Dec 3, 2021
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Jan 21, 2026

Study contacts

Joseph Broderick, MD
principal investigator · University of Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion